The Impact of MTM Model on the Efficacy and Safety of Anticoagulant Therapy in Postoperative Colorectal Cancer Patients

Recruiting now · Not applicable

Conditions studied: Thrombosis, Venous

In brief

Anticoagulants are classified as high-risk medications, with their main adverse drug events (ADEs) being recurrent venous thromboembolism (VTE) and bleeding events.Postoperative colorectal cancer (CRC) patients exhibit a high probability of recurrent VTE and bleeding during anticoagulation therapy.The Medication Therapy Management (MTM) model will contribute to reducing ADEs associated with anticoagulants in CRC patients.

Key facts

Study ID

NCT06998745

Run by

Sixth Affiliated Hospital, Sun Yat-sen University

People needed

327

Starts

2025-05-01

Expected to finish

2027-12-30

Last updated by the study team

2025-05-31

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically confirmed CRC and symptomatic or incidental VTE who received anticoagulant treatment.
• CRC patients with VTE treated with an anticoagulant for at least 3 moths.

You may not qualify if…

• Participation in this study required active anticoagulant treatment. Apart from this, there were no specific exclusion criteria.

Where it is running

• Sixth Affiliated Hospital, Sun Yat-sen University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.